AG-CANDESARTAN TABLETS

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

CANDESARTAN CILEXETIL

Mevcut itibaren:

ANGITA PHARMA INC.

ATC kodu:

C09CA06

INN (International Adı):

CANDESARTAN

Doz:

16MG

Farmasötik formu:

TABLET

Kompozisyon:

CANDESARTAN CILEXETIL 16MG

Uygulama yolu:

ORAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Terapötik alanı:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0135220003; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2020-06-22

Ürün özellikleri

1
PRODUCT MONOGRAPH
Pr
AG-Candesartan Tablets
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Angiotensin II
AT
1
Receptor Blocker
Date of Revision:
June 19, 2020
Submission
Control
No.:
239327
J4B 5H3
Boucherville
,
Québec
1310
rue
Nobel
Angita Pharma Inc.
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE RE ACT IONS
..................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOS AGE AND AD MINISTRAT IO
N.........................................................................
18
O V E RD O SA GE
..........................................................................................
21
ACTION AND CLINICAL PHARMAC OLOGY
................................................... 21
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
.................................................................................25
PHARMACEUTICAL INFORMATION
25
CLINICAL TRIALS
..........................................................................................................
26
DET AIL ED PHARMACO LOG Y
.................................................................................
30
TO XI COL O G Y
................................